TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TMDX 12.12.2024

Full Press ReleaseSEC FilingsOur TMDX Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - TransMedics Responds to Inaccurate and Misleading Claims in Recent Short-Seller Report
  • 12.23.2024 - TransMedics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.14.2025 - 8-K Current report
  • 01.10.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.06.2024 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors

ANDOVER, Mass.,Dec. 12, 2024/PRNewswire/ --TransMedics Group, Inc.("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that onDecember 9, 2024,TransMedicsgranted non-qualified stock options to purchase an aggregate of 20,612 shares of its common stock and an aggregate of 13,576 restricted stock units to 3 employees, each as a material inducement for each employee's entry into employment withTransMedics. The grants included stock options to purchase 18,922 shares ofTransMedics'common stock and 12,463 restricted stock units granted toGerardo Hernandez, the Company's Chief Financial Officer. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to theTransMedics Group, Inc.Inducement Plan.

(PRNewsfoto/TransMedics, Inc.)

TransMedicsgranted non-qualified stock options to purchase 20,612 shares ofTransMedics'common stock and 13,576 restricted stock units in the aggregate. The stock options were granted with a per share exercise price of$69.84, the closing price of the common stock on the Nasdaq Global Market onDecember 9, 2024. Twenty-five percent of the shares subject to each option will vest on the first yearly anniversary of the date of the employee's start of employment, with the remainder vesting in equal monthly installments over the subsequent three year period, subject to the employee's continued service with the Company through the applicable vesting date. The options have a 10-year term and are subject to the terms of theTransMedics Group, Inc.Inducement Plan. Twenty-five percent of each restricted stock unit award will vest on the first four anniversaries of the date of the employee's start of employment, subject to the employee's continued service with the Company through the applicable vesting date. The restricted stock units are subject to the terms of theTransMedics Group, Inc.Inducement Plan.

AboutTransMedics Group, Inc.TransMedicsis the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered inAndover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:Brian Johnston332-895-3222Investors@transmedics.com

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302330724.html

SOURCETransMedics Group, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com